PDF(Pubmed)
Abstract：
Alzheimer\'s disease (AD) is the most widespread and irreversible form of dementia and accounts for more than half of dementia cases. The most significant risk factors for AD are aging-related exacerbations, degradation of anatomical pathways, environmental variables and mitochondrial dysfunction. Finding a decisive therapeutic solution is a major current issue. Nuanced interactions between major neuropathological mechanisms in AD in patients and microbiome have recently gained rising attention. The presence of bacterial amyloid in the gut triggers the immune system, resulting in increased immune feedbacks and endogenous neuronal amyloid within the CNS. Also, early clinical research revealed that changing the microbiome with beneficial bacteria or probiotics could affect brain function in AD. New approaches focus on the possible neuroprotective action of disease-modifying medications in AD. In the present review, we discuss the impact of the gut microbiota on the brain and review emerging research that suggests a disruption in the microbiota-brain axis can affect AD by mediating neuroinflammation. Such novel methods could help the development of novel therapeutics for AD.
摘要：
阿尔茨海默病（AD）是痴呆的最普遍和最不可逆的形式，占痴呆病例的一半以上。AD最重要的危险因素是与衰老相关的恶化，解剖通路的退化，环境变量和线粒体功能障碍。找到决定性的治疗解决方案是当前的主要问题。AD患者的主要神经病理学机制与微生物组之间的细微差别的相互作用最近受到越来越多的关注。肠道中细菌淀粉样蛋白的存在会触发免疫系统，导致中枢神经系统内免疫反馈和内源性神经元淀粉样蛋白增加。此外，早期的临床研究表明,用有益细菌或益生菌改变微生物组可能会影响AD患者的脑功能.新方法集中于AD中疾病改善药物的可能的神经保护作用。在本次审查中，我们讨论了肠道微生物群对大脑的影响,并回顾了新兴的研究,这些研究表明微生物群-脑轴的破坏可通过介导神经炎症影响AD.这样的新方法可以帮助开发用于AD的新疗法。
